Bellerophon's heart device fails study

[July 27, 2015]   (Reuters) - Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe.

The device, Bioabsorbable Cardiac Matrix (BCM), was tested in 303 patients who had already suffered a heart attack.

The device was licensed to Bellerophon by BioLineRx Ltd in 2009.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Kirti Pandey)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.